JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Aclaris Therapeutics Inc

Search

Aclaris Therapeutics Inc

Suletud

4.41 1.85

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.33

Max

4.41

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M -20M
Müük	-2M 1.3M
Kasumimarginaal	-1,528.571
Töötajad	69
EBITDA	-5.3M -20M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+156.92% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	264M 616M
Eelmine avamishind	2.56
Eelmine sulgemishind	4.41

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.28 / 1.33 Toetus ja vastupanu

Aclaris Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 22:17 UTC

Tulu

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4. mai 2026, 23:47 UTC

Tulu

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4. mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Regis: Jim Beyer To Be Chief Executive of Combined Company

4. mai 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Shareholders to Own About 51% of Combined Company

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Board Unanimously Endorsed, Supported Deal

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Deal Unanimously Recommended by Vault Board

4. mai 2026, 22:39 UTC

Omandamised, ülevõtmised, äriostud

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources to Acquire All Ordinary Shares in Vault

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources, Vault Minerals Agree to Merger of Equals

4. mai 2026, 22:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4. mai 2026, 22:26 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4. mai 2026, 22:02 UTC

Tulu

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4. mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4. mai 2026, 21:52 UTC

Tulu

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4. mai 2026, 21:50 UTC

Tulu

Westpac: Some Sectors More Affected Than Others>WBC.AU

4. mai 2026, 21:50 UTC

Tulu

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4. mai 2026, 21:49 UTC

Tulu

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4. mai 2026, 21:43 UTC

Tulu

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4. mai 2026, 21:41 UTC

Tulu

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4. mai 2026, 21:40 UTC

Tulu

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Võrdlus sarnastega

Hinnamuutus

Aclaris Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

156.92% tõus

12 kuu keskmine prognoos

Keskmine 11.33 USD 156.92%

Kõrge 16 USD

Madal 10 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Aclaris Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Põhineb 6 analüütiku instrumendi Aclaris Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.28 / 1.33Toetus ja vastupanu

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat